The effects of interferon-a on cytokines and immune responses

Interferon Therapy of Multiple Sclerosis

Volumn , Issue , 1997, Pages 161-192

  Rieckmann, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0004716474     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (169)

1. Jacobs LD, O'Malley, Freeman A, Akes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214:1026-1028.
2. Arnason BGW, Reder AT. Interferons and multiple sclerosis. Clin Neuropharmacol 1994; 17:1-53.
3. Paty DW, Li DKB, Group UMS, Group IFN-β MSS. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:662-667.
4. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-294.
5. Panitch HS, Bever CJ. Clinical trials of interferons in multiple sclerosis. What have we learned? J Neuroimmunol 1993; 46:155-164.
6. Arnason BGW. Editorial: Interferon beta in multiple sclerosis. Neurology 1993; 43:641-643.
7. Smith RA, Norris F, Palmer D, Bernhardt L, Wills RJ. Distribution of interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985; 37:85-88.
8. Burke DC, Shuttleworth J. The control of interferon alpha and interferon beta gene expression. In: Friedman RM, ed. Interferon. Vol. . Mechanisms of Production and Action. New York, Elsevier 1984:85-111.
9. Field AK, Tytell AA, Lampson GP, Hilleman MR. Inducers of interferons and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci USA 1967; 58:1004-1010.
10. Capobianchi MR, Facchini J, di Marco P, Antonelli G, Dianzani F. Induction of alpha interferon by membrane interaction between viral surface and peripheral blood mononuclear cells. Proc Soc Exp Biol Med 1985; 178: 551-556.
11. Gessani S, Puddu P, Varano B, Borghi P, Conti L, Fantuzzi L, Belardelli F. Induction of beta interferon by human immunodeficiency virus type 1 and its gp120 protein in human monocytes-macrophages: role of beta interferon in restriction of virus replication. J Virol 1994; 68:1983-1986.
12. Bermudez LE. Infection of "Nonprofessional" phagocytes with mycobacterium avium complex. Clin Immunol Immunopathol 1991; 61:225-235.
13. De Mayer E, De Mayer-Guignard J. Interferons and Other Regulatory Cytokines. New York: Wiley, 1988.
14. Gessani S, Belardelli F, Pecorelli A, Puddu P, Baglioni C. Bacterial lipopolysaccharide and gamma interferon induce transcription of beta interferon mRNA and interferon secretion in murine macrophages. J Virol 1989; 63: 2785-2789.
15. Cleveland MG, Lane RG, Klimpel GR. Enhanced interferon-alpha/beta and defective IFN-gamma production in chronic graft versus host disease: A potential mechanism for immunosuppression. Cell Immunol 1987; 110: 120-130.
16. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, Vileek J, Zinkernagel RM, Aguet M. Immune responses in mice that lack the interferon-gamma receptor. Science 1993; 259:1742-1745.
17. Pyo S, Gangemi JD, Ghaffer A, Mayer EP. Poly LC—induced anti-herpes simplex virus type 1 activity in inflammatory macrophages is mediated by induction of interferon-beta. J Leukocyte Biol 1991; 50:479-487.
18. Riches DWH, Underwood GA. Expression of interferon-β during the triggering phase of macrophage cytocidal activation: Evidence for an autocrine/paracrine role in the regulation of this state. J Biol Chem 1991; 266: 24785-24792.
19. Shemer AY, Wallach D, Sarov I. Reversion of the antichlamydial effect of tumor necrosis factor by tryptophan and antibodies to beta interferon. Infect Immun 1989; 57:3484-3490.
20. Onozaki K, Urawa H, Tamatani T, Iwamura Y, Hashimoto T, Baba T, Suzuki H, Yamada M, Yamamoto S, Oppenheim JJ, Matsushima K. Synergistic interactions of interleukin-1, interferon-beta, and tumor necrosis factor in terminally differentiating a mouse myeloid leukemic cell line (M1). J Immunol 1988; 140:112-119.
21. Testa, U, Ferbus D, Gabbianelli M, Pascucci B, Boccoli G, Louache F, Thang MN. Effect of endogenous and exogenous interferons on the differentiation of human monocyte cell line U937. Cancer Res 1988; 48:82-88.
22. Stout RD, Suttles J. Evidence for involvement of TNF-alpha in the induction phase and IFN-β in the effector phase of antiproliferative activity of splenic macrophages. Cell Immunol 1992; 139:363-374.
23. Zhang X, Alley EW, Russell SW, Morrison DC. Necessity and sufficiency of beta interferon for nitric oxide production in mouse peritoneal macrophages. Infect Immun 1994; 62:33-40.
24. Moore RN, Larsen HS, Horohov DW, Rouse BT. Endogenous regulation of macrophage proliferative expansion by colony-stimulating factor—induced interferon. Science 1984; 223:178-181.
25. Cederblad B, Alm GF. Interferons and the colony-stimulating factors IL- 3 and GM-CSF enhance the IFN-alpha response in human blood leucocytes induced by herpes simplex virus. Scand J Immunol 1991; 34:549-555.
26. Seghal PB, Gupta SL. Regulation of the stability of poly(I):poly(C) induced human fibroblast interferon mRNA: selective inactivation of interferon mRNA and lack of involvement of 2'5'-oligo(A) synthetase activation during shut-off of interferon production. Proc Natl Acad Sci USA 1980; 77: 3849-3893.
27. Gobl AE, Funa K, Alm GV. Different induction pattern of mRNA for IFNalpha and -beta in human mononuclear leukocytes after in vitro stimulation with Herpes simplex virus-infected fibroblasts and Sendai virus. J Immunol 1988 ; 140:3605-3609.
28. Gobl AE, Cederblad B, Sandberg K, Alm GV. Interferon-a but not -0 genes require de novo protein synthesis for efficient expression in human monocytes. Scand J Immunol 1992; 35:177-185.
29. Gendelman HE, Friedman RM, Joe S, Baca LM, Turpin JA, Dveksler G, Meltzer MS, Dieffenbach C. A selective defect of interferon alpha production in human immunodeficiency virus-infected monocytes. J Exp Med 1990; 172:1433-1442.
30. Mossman TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RI. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
31. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76: 241-251.
32. Heinzel FP, Schoenhut DS, Rerko RM, Rosser LE, Gately MK. Recombinant IL-12 cures mice infected with Leishmania major. J Exp Med 1993; 177:1505-1509.
33. Balachov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Defective regulation of T-cell receptor—mediated IFN-gamma production by Th2-type cytokines in multiple sclerosis. Neurology 1995; 45(suppl 4):A384.
34. Powrie F, Coffman RL. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today 1993; 14:270-274.
35. Clerici M, Shearer GM. A Thl-Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14:107-111.
36. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16:34-38.
37. + T cells is required for their entry into brain parenchyma. J Exp Med 1993; 177:57-68.
38. Miller SD, Karpus WJ. The immunopathogenesis and regulation of T - cellmediated demyelinating diseases. Immunol Today 1994; 15:356-361.
39. Brod SA, Benjamin D, Hafler D. Restricted T cell expression of IL-2/IFNy mRNA in human inflammatory diseases. J Immunol 1991; 147:810-815.
40. Weber F, Meinl E, Drexler K, Czlonkowska A, Huber S, Fickenscher H, Mtiller-Fleckenstein I, Fleckenstein B, Wekerle H, Hohlfeld R. Transformation of human T cell clones by herpesvirus saimiri: intact antigen recogni ion by autonomously growing myelin basic protein-specific T cells. Proc Natl Acad Sci USA 1993; 90:11049-11053.
41. Link J, Soderstrom M, Ljungdahl A, Hojeberg B, Olsson T, Xu Z, Fredrikson S, Wang ZY, Link H. Organ-specific autoantigens induce interferongamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology 1994; 44:728-734.
42. Olsson T, Zhi WW, Hojeberg B, Kostulas V, Yu-Ping J, Anderson G, Ekre HP, Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-y. J Clin Invest 1990; 86:981-985.
43. Benvenuto R, Paroli M, Buttinelli C, Franco A, Barnaba V, Fieschi C, Balsano F. Tumor necrosis factor-alpha and interferon-gamma synthesis by cerebrospinal fluid-derived T cell clones in multiple sclerosis. Ann NY Acad Sci 1991; 341-346.
44. Gajewski TF, Schell SR, Nau G, Fitch FW. Regulation of T-cell activation: differences among T cell subsets. Immunol Rev 1989; 111:79-110.
45. Hardy KJ, Manger B, Newton M, Stobo JD. Molecular events involved in regulating human interferon-gamma gene expression during T cell activation. J Immunol 1987; 138:2353-2358.
46. Munakata T, Semba U, Shibuya Y, Kuwano K, Akagi M, Arai S. Induction of interferon-y production by human T cells stimulated by hydrogen peroxide. J Immunol 1985; 134:2449-2455.
47. Ianaro A, O'Donnell CA, Di-Rossa M, Liew FY. A nitric oxide synthase inhibitor reduces inflammation, down-regulates inflammatory cytokines and enhances interleukin-10 production in carrageenin-induced oedema in mice. Immunology 1994; 82:370-375.
48. Johnson HM, Torres BA. Leukotrienes: positive signals for regulation of gamma-interferon production. J Immunol 1984; 132:413-416.
49. Le J, Lin JX, Henriksen-DeStefano D, Vilcek J. Bacterial lipolpolysaccharide- induced interferon-gamma production: roles of interleukin 1 and interleukin 2. J Immunol 1986; 136:4525-4530.
50. Farrar MA, Schreiber RD. The molecular cell biology of interferon-y and its receptor. Ann Rev Immunol 1993; 11:571-611.
51. Langer JA, Pestka S. Interferon receptors. Immunol. Today 1988; 9: 393-400.
52. Noronha A, Toscas A, Jensen MA. Interferon β decreases T cell activation and interferon y production in multiple sclerosis. J Neuroimmunol 1993; 46:145-154.
53. + T cells. J Exp Med 1993; 178:1655-1663.
54. Bednarik DP, Mosca JD, Babu N, Raj K, Pitha PM. Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha2- interferon. Proc Natl Acad Sci USA 1989; 86:4958-4962.
55. Gendelman HE, Baca LM, Kubrak CA, Genis P, Burrous S, Friedman RM, Jacobs D, Meltzer MS. Induction of interferon alpha in peripheral blood ononuclear cells by human immunodeficiency virus (HIV)-infected monocytes: restricted antiviral activity of the HIV-induced interferons. J Immunol 1992; 148:422-430.
56. Del Gobbo V, Foli A, Balzarini J, EDC, Balestra E, Villani N, Marini S, Perno CF, Calio R. Immunomodulatory activity of 9-(2-phosphonyl-methoxyethyl) adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res 1991; 16:65-75.
57. Yoshihara R, Shiozawa S, Fujita T, Chihara K. Gamma interferon is produced by human natural killer cells but not T cells during Staphylococcus aureus stimulation. Infect Immun 1993; 61:3117-3122.
58. Wherry JC, Schreiber RD, Unanue ER. Mechanism of interferon-gamma production by natural killer cells in scid mice. FASEB J 1990; 4:A1701.
59. Reiter Z, Rappaport B. Dual effects of cytokines in regulation of MHCunrestricted cell mediated cytotoxicity. Crit Rev Immunol 1993; 13:1-34.
60. + null lymphocytes produce IFN-alpha after stimulation by herpes simplex virus-infected cells. J Immunol 1990; 145:1015-1020.
61. Feldman SB, Ferraro M, Zheng HM, Patel N, Gould-Fogerite S, Fitzgerald- Bocarsly P. Viral induction of low frequency interferon-alpha producing cells. Virology 1994; 204:1-7.
62. Howell D, Feldman S, Kloser P, Fitzgerald-Bocarsly P. Decreased frequency of natural interferon producing cells in peripheral blood of patients with the acquired immune deficiency syndrome. Clin Immunol Immunopathol 1994; 71:223-230.
63. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 2:1313-1315.
64. Allen I, Brankin B. Pathogenesis of multiple sclerosis-the immune diathesis and the role of viruses. J Neuropathol Exp Neurol 1993; 52:95-105.
65. Capobianchi M, Malavasi F, DiMarco P, Dianzani F. Differences in the mechanism of induction of interferon-alpha by herpes simplex virus and herpes-simplex virus-infected cells. Arch Virol 1988; 103:219-229.
66. Wiranowska-Stewart M, Stewart W. Determination of human leukocyte populations involved in production of interferons alpha and gamma. J Interferon Res 1981; 1:233-244.
67. Weigent DA, Langford MP, Smith EM, Blalock JE, Stanton GJ. Human B lymphocytes produce leukocyte interferon after interaction with foreign cells. Infect Immun 1981; 32:508-512.
68. Kehrl JH, Miller A, Fauci AS. Effect of tumor necrosis factor a on mitogenactivated human B cells. J Exp Med 1987; 166:786-791.
69. + blood dendritic cells are potent producers of IFN-a in response to in vitro HIV- 1 infection. J Immunol 1994; 152:4649-4662.
70. Van Damme J, GO. Interaction of interferons with skin-reactive cytokines: from interleukin-1 to interleukin-8. J Invest Dermatol 1990; 95:90S-93S.
71. Van Damme J, Schaafsma MR, Fibbe WE, Falkenburg JHF, Opdenakker G, Billiau A. Simultaneous production of interleukin 6, interferon-beta and olony-stimulating activity by fibroblasts after viral and bacterial infection. Eur J Immunol 1989; 19:163-168.
72. Lenardo MJ, Fan CM, Maniatis T, Baltimore D. The involvement of NFKB in beta-interferon gene regulation reveals its role as widely inducible mediator of signal transduction. Cell 1989; 57:287-294.
73. Mathiesen GA, Toth FD, Juhl C, Ladritsen NN. Purification and initial characterization of human placental trophoblast interferon induced by polyriboinosinic polyribocytidylic acid. J Gen Virol 1990; 71:3061-3066.
74. Tao YX, Cao YQ. Modulation of interferon secretion by concanavalin A and interleukin-2 in first trimester placental explants in vitro. J Reprod Immunol 1993; 24:201-212.
75. Pociot F, Wilson AG, Nerup J, Duff GW. No independent association between a tumor necrosis factor-alpha promotor region polymorphism and insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23:3050-3053.
76. Salonen R, Ilonen J, Reunanen M, Salmi A. Defective production of interferon- y associated with HLA-DW2 antigen in stable multiple sclerosis. J Neurol Sci 1982; 55:197-206.
77. Tovell DR, McRobbie IA, Warren KG, Tyrell DLJ. Interferon production by lymphocytes from multiple sclerosis and non-MS patients. Neurology 1983; 33:640-643.
78. Bocci V. The physiological interferon response. Immunol Today 1985; 6: 7-9.
79. Knight EJ, Anton ED, Fahey D, Friedland BK, Jonak GJ. Interferon regulates c-myc gene expression in Daudi cells at the post-transcriptional level. Proc Natl Acad Sci USA 1985; 82:1151-1154.
80. Einat M, Resnitzky D, Kimchi A. Close link between reduction of c-myc expression by interferon and, G0/G1 arrest. Nature 1985; 313:597-600.
81. Pfeffer LM, Donner B, Tamm I. Interferon-alpha down-regulates insulin receptors in lymphoblastoid (Daudi) cells. Relationship to inhibition of cell proliferation. J Biol Chem 1987; 262:3665-3670.
82. Aggarawal BB, Eessalu TE, Has PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma interferon. Nature 1985; 318:665-667.
83. Roth AD, Abele R, Alberto P. 13-cis-retinoic acid plus interferon-alpha: a phase II clinical study in squamous cell carcinoma of the lung and the head and neck. Oncology 1994; 51:84-86.
84. Metha K, McQueen T, Tucker S, Pandita R, Aggarwal BB. Inhibition by all-trans-retinoic acid of tumor necrosis factor and nitric oxide production by peritoneal macrophages. J Leukoc Biol 1994; 55:336-342.
85. Dickens TA, Colletta AA. The pharmacological manipulation of members of the transforming growth factor beta family in the chemoprevention of breast cancer. Bioassays 1993; 15:71-74.
86. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ. Protective effect of transforming growth factor /3i on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991; 88: 2918-21.
87. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Ltier W, Helwig A, Poser S. Tumor necrosis factor-a messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995; 37:82-88.
88. Sidman CL, Marshall JD, Shultz LD, Gray PW, Johnson HM. Gamma interferon is one of several direct B cell-maturing lymphokines. Nature 1984; 309:801-804.
89. Bansil S, Cook SD, Rohowsky-Kochan C. Multiple sclerosis: immune mechanism and update on current therapies. Ann Neurol 1995; 37(suppl 1): S87-S101.
90. Briskin M, Kuwabara MD, Sigman DS, Wall R. Induction of kappa transcription by interferon-gamma without activation of NF-KB. Science 1988; 258:1036-1037.
91. Cowdery JS, Fleming AL. In vivo depletion of CD4 T cells increases B cell sensitivity to polyclonal activation: the role of interferon-y. Clin Immunol Immunopathol 1992; 62:72-78.
92. Snapper CM, Peschel C, Paul WE. IFN-y stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J Immunol 1988; 140:2121-2127.
93. Chen U. Analysis of cell proliferation and p.-RNA procesing during activation of mouse B cells by anti-μ and T lymphokines. Mol Immunol 1990; 27: 1249-1257.
94. Abed NS, Chace JH, Fleming AL, Cowdery JS. Interferon-gamma regulation of B lymphocyte differentiation. Cell Immunol 1994; 153:356-366.
95. Rieckmann P, Weber T, Felgenhauer K. Class differentiation of immunoglobulin- containing cerebrospinal fluid cells in inflammatory diseases of the central nervous system. Klin Wochenschrift 1990; 68:12-17.
96. Olsson T. Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-y. J Neuroimmunol 1992; 40:211-218.
97. Mayet WJ, Hess G, Gerken G. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989; 10:24-28.
98. Drapier JC, Wietzerbin J, Hibbs JJ. Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 18:1587-1592.
99. Oswald IP, Wynn TA, Sher A, James SL. NO as an effector molecule of parasite killing: modulation of its synthesis by cytokines. Comp Biochem Physiol Pharmacol Toxicol Endocrinol 1994; 108:11-18.
100. Alleva DG, Burger CJ and Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-a production. Role of tumor-derived IL-10, TGF-/3, and prostaglandin E2. J Immunol 1994; 153:1674-1686.
101. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, Kong PA, Hanley D, Trapp BD. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994; 36:778-786.
102. Koprowski H, Zheng YM, Heber-Katz E, Fraser N, Rorke L, Fu ZF, Hanlon C, Dietzschold B. In vivo expression of inducible nitric oxide synthase n experimentally induced neurologic diseases. Proc Natl Acad Sci USA 1993; 90:3024-3027.
103. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23:339-346.
104. Sheehan, KCF, Schreiber RD. The synergy and antagonism of interferony and TNF. In: Beutler B, ed. Tumor Necrosis Factors. New York: Raven Press, 1992; 145-178.
105. Collart, MA, Belin D, Vassalli JD, de Kossodo S, Vassalli P. y Interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J Exp Med 1986; 164:2113-2118.
106. Kamijo, R, Le J, Shapiro D, Havell EA, Huang S, Aguet M, Bosland M, Vileek J. Mice lacking the interferon-y receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharides. J Exp Med 1993; 178:1435-1440.
107. Wherry, JC, Schreiber RD, Unanue ER. Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli. Infect Immun 1991; 59:1709-1715.
108. 107a. Wenner CA, Giller ML, Macatonia SE, O'Garra A, Murphy KM. Roles of IFN-y and IFN-a in IL-12-induced T helper cell-1 development. J Immunol 1996; 156:1442-1447.
109. Herrmann F, Cannistra SA, Lindemann A, Blohm D, Rambaldi A, Mertelsmann RH, Griffin JD. Functional consequences of monocyte IL-2 receptor expression: induction of IL-10 secretion by IFN-y and IL-2. J Immunol 1989; 142:139-143.
110. Olsson T. Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis. Eur J Neurol 1994; 1:7-19.
111. Springer T. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76:301-314.
112. Cannella B, Cross All, Raine CS. Adhesion-related molecules in the central nervous system. Upregulation correlated with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. Lab Invest 1991; 65:23-31.
113. Peleman R, Wu J, Fargeas C, Delespesse G. Recombinant interleukin 4 suppresses the production of interferon y in human mononuclear cells. J Exp Med 1989; 170:1751-1756.
114. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Thl cells. J Immunol 1991; 146:3444-3451.
115. Minty A, Chalon P, Derocq JM, Dumont X, Guillemont JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B, Minty C, Casellas P, GL, Lupker J, Shire D, Ferrara P, Caput D. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993; 362:248-250.
116. Tsunawaki S, Sporn M, Ding A, Nethan C. Deactivation of macrophages by transforming growth factor-β. Nature 1988; 334:260-262.
117. Pober JS, Gimbrone MA, Lapierre LA. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor and immune interferon. J Immunol 1986; 22:219-226.
118. Kasahara T, Hooks JJ, Dougherty SF, Oppenheim JJ. Interleukin-2 mediated immune interferon (IFN-y) production by human T cells and T cell subsets. J Immunol 1983; 130:1784-1789.
119. Kubin M, Kamoun M, Trinchieri G. IL-12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production in human T cells. J Exp Med 1994; 180:211-222.
120. Porrini, AM, Reder AT. IFN-y, IFN-0 and PGE1 affect monokine secretion: relevance to monocyte activation in multiple sclerosis. Cell Immunol 1994; 157:428-438.
121. Skias DD, Reder AT. IL-10 inhibits EAE. Neurology 1995; 45(suppl 4): A349.
122. Jacobsen H, Mestan J, Mittnacht S, Dieffenbach CW. Beta interferon subtype 1 induction by tumor necrosis factor. Mol Cell Biol 1989; 9:3037-3042.
123. Noronha A, Toscas A, Jensen MA. IFN-beta modulates immune function: implication for multiple sclerosis. J Immunol 1993; 150:A259.
124. Abu-Khabar KS, Armstrong JA, Ho M. Type I interferons (IFN-α and β) suppress cytotoxin (tumor necrosis factor-a and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J Leukoc Biol 1992; 52:165-172.
125. Shakir S, Byskosh PV, Reder AT. Interferon beta induces interleukin-10 mRNA in mononuclear cells (MNC). Neurology 1994; 44(suppl 2): A211-A212.
126. 124a. Tilg H, Mier JW, Vogel W, et al. Induction of circulating IL-1 receptor antagonists by IFN treatment. J Immunol 1993; 150:4687-4692.
127. Faulds D, Benfield P. Interferon β-lb in multiple sclerosis. Clin Immunother 1994; 1:79-87.
128. Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M. Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44:406-413.
129. Durelli L, Bongioanni MR, Ferrero B, Verdun E, Riva A, Geuna M, Bradac GB, Bergamasco B, Bergamini L. Chronic alpha interferon (IFN-a) treatment for multiple sclerosis (MS) modulates cytokine production rather than antigen presentation. Neurology 1995; 45(suppl 4):A234.
130. Twardzik DR, Mikovitis JA, Ranchalis JE, Purchio AF, Ellingsworth L, Ruscetti FW. y interferon-induced activation of latent transforming growth factor-/3 by human monocytes. Ann NY Acad Sci 1990; 593:276-284.
131. Klimple GR, Fleischman WR, Klimple KD. Gamma interferon (IFN) and IFNα/β suppress murine myeloid colony formation (CFV-C): magnitude of suppression is dependent upon level of colony stimulating factor (CSF). J Immunol 1982; 129:76-80.
132. Van-Damme J, Proost P, Put W, Arens S, Lenaerts JP, Conings R, Op denakker G, Heremans H, Billiau A. Induction of monocyte chemotactic proteins MCP-1 and MCP-2 in human fibroblasts and leukocytes by cytokines and cytokine inducers. J Immunol 1994; 152:5495-5502.
133. Brown Z, Gerritsen ME, Carley WW, Strieter RM, Kunkel SL, Westwick J. Chemokine gene expression and secretion by cytokine-activated human chemoattractant protein-1 and interleukin-8 in response to interferongamma. Am J Pathol 1994; 145:913-921.
134. Morita M, Kasahara T, Mukaida N, Matsushima K, Nagashima T, Nishizawa M, Yoshida M. Induction and regulation of IL-8 and MCAF production in human brain tumor cell lines and brain tumor tissues. Eur Cytokine Netw 1993; 4:351-358.
135. Tani M, Ransohoff RM. Do chemokines mediate inflammatory cell invasion of the central nervous system parenchyma? Brain Pathol 1994; 4:135-143.
136. Fabry Z, Raine CS, Hart MN. Nervous tissue as an immune compartment: the dialect of the immune response with the CNS. Immunol Today 1994; 15:218-224.
137. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987; 238:522-524.
138. Reder AT, Lowy MT. Interferon-0 treatment does not elevate cortisol in multiple sclerosis. J Interferon Res 1992; 12:195-198.
139. Hansen TR, Imakawa K, Polites HG, Marotti KR, Anthony RV, Roberts RM. Interferon mRNA of embryonic origin is expressed transiently during early pregnancy. J Biol Chem 1988; 263:12801-12804.
140. Altmann DJ, Schneider SL, Thompson DA, Cheng HL, Tomasi TB. A transforming growth factor-β2 (TGF-02)-like immunosuppressive factor in amniotic fluid and localization of TGF-/32 mRNA in the pregnant uterus. J Exp Med 1990; 172:1391-1401.
141. Dayal A, Ismail MA, Jensen M, Lledo A, Arnason BGW. Pregnancy plasma inhibits interferon gamma-secreting cells in multiple sclerosis. Neurology 1995; 45(suppl 4):A197.
142. Evavold BD, Sloan-Lancaster J, Allen PM. Tickling the TCR: selective T cell function stimulated by altered peptide ligands. Immunol. Today 1993; 14:602-606.
143. Basham TY, Merigan TC. Recombinant interferon-y increases HLA-DR synthesis and expression. J Immunol 1983; 130:1492-1494.
144. Armstrong MA, Crockard AD, Hawkins SA, McNeill TA. Multiple sclerosis and gamma interferon. Lancet 1987; 1:1369-1370.
145. Panitch HS, Folus JS, Johnson KP. Beta interferon prevents HLA class II antigen induction by gamma interferon in MS. Neurology 1989; 39(suppl 1):171.
146. 143a. Soilu-Hanninen M, Salmi A, Salonen R. Interferon-a downregulates expression of VLA-4 antigen and antagonizes interferon-y-induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol 1995; 60:99-106.
147. Ransohoff RM, Tuohy VK, Barna BP, Rudick RA. Monocytes in active multiple sclerosis: intact regulation of HLA-DR density in vitro despite decreased HLA-DR density in vivo. J Neuroimmunol 1992; 37:169-176.
148. Hartung HP. Immune-mediated demyelination. Ann Neurology 1993; 33: 563-567.
149. Washington R, Burton J, Todd R, Newman W, Dragovic L, Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994; 35:89-97.
150. Sobel RA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990; 136:1309-1316.
151. Alosi F, Borsellino G, Samoggia P, Testa U, Chelucci C, Russo G, Peschle C, Levi G. Astrocyte cultures from human embryonic brain: characterization and modulation of surface molecules by inflammatory cytokines. J Neurosci Res 1992; 32:494-506.
152. Cross H. Immune cell traffic control and the central nervous system. Semin Neurosci 1992; 4:213-219.
153. Wong D, Dorovini-Zis K. Upregulation of intercellular adhesion molecule- 1 (ICAM-1) expression in primary cultures of human brain microvessel endothelial cells by cytokines and lipopolysaccharide. J. Neuroimmunol 1992; 39:11-22.
154. Ziesalek J, Archelos JJ, Toyka KV, Hartung HP. Expression of intercellular adhesion molecule-1 on rat microglial cells. Neurosci Lett 1993; 153: 136-139.
155. Westermann J, Persin S, Matyas J, P VDM, Pabst R. IFN-y influences the migration of thoracic duct B and T lymphocytes subsets in vivo: random increase in disappearance from the blood and differential decrease reappearance in the lymph. J Immunol 1993; 150:3843-3852.
156. Fedoseyeva EV, Li Y, Huey B, Tam S, Hunt CA, Benichou G, Garovoy MR. Inhibition of interferon-gamma-mediated immune functions by oligonucleotides. Suppression of human T cell proliferation by downregulation of IFN-gamma-induced ICAM-1 and Fc-receptor on accessory cells. Transplantation 1994; 57:606-612.
157. Willems F, Marchant A, Delville JP, Gerard C, Delvaux A, Velu T, de Boer M, Goldman M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24: 1007-1009.
158. Reder AT. IFN-/3 and IFN-y modify expression of monocyte surface proteins. J Interferon Res 1991; 11(suppl 1):121.
159. Rudick RA, Carpenter CS, Cookfair DL, Tuohy VK, Ransohoff RM. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 1993; 43:2080-2087.
160. Antel J, Bania MB, Reder AT, Cashman N. Activated suppressor cell dysfunction in progressive multiple sclerosis. J. Immunol 1985; 137:137-141.
161. Noronha A, Toscas A, Arnason BGW, Jensen M. IFN-beta augments in vivo suppressor function in MS. Neurology 1994; 44(suppl 2):A212.
162. Endres S, Fulle HJ, Sinha B, Stoll D, Dinarello CA, Gerzer R, Weber PC. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. Immunology 1991; 72:56-60.
163. Ferreri NR, Sarr T, Askenase PW, Ruddle NH. Molecular regulation of tumor necrosis factor-alpha and lymphotoxin production in T cells: inhibition by prostaglandin E 2. J Biol Chem 1992; 267:9443-9449.
164. Philips RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. Immunol Today 1991; 12:349-352.
165. Dore-Duffy P, Donaldson JO, Koff T, Longo M, Perry W. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology 1986; 36:1587-1590.
166. Reder AT, Thapar M, Sapugay AM, Jensen MA. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol 1994; 54:117-127.
167. Boraschi D, Soldateschi D, Tagliabue A. Macrophage activation by interferon: dissociation between tumoricidal capacity and suppressive activity. Eur J Immunol 1982; 12:320-326.
168. Heremans H, Dillen C, Dijkmans A, Grau G, Billiau A. The role of cytokines in various animal models of inflammation. Lymphokine Res 1989; 8: 329-333.
169. Liu Y, Janeway CAJ. Interferon y plays a critical role in induced cell death of effector T cells: a possible third mechanism of self-tolerance. J Exp Med 1990; 172:1735-1739.